Madrigal Pharmaceuticals MDGL
United StatesHealthcare · BiotechnologyUSD
682.11 USD (+39.9%)
18 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Madrigal Pharmaceuticals is a commercial-stage biotech that develops and sells Rezdiffra, the first approved treatment for non-alcoholic steatohepatitis (MASH/NASH), a chronic liver disease with a large patient population and no prior therapeutic options.
Key points
from its scores- ✓Strong growth10.0
- ✓Favourable backdrop9.2
- ✕Demanding valuation1.1
- ✕Little or no dividend1.5
- ✕Little competitive advantage3.3
AI analysis
bottom line, main risk, context and newsRezdiffra's potential is real, but profitability and valuation depend on the drug's adoption speed and future competition.
Madrigal combines exceptional revenue growth (71.20%) with a 91.48% gross margin and a solid balance sheet (liquidity 3.21, net debt/EBITDA 1.53), but remains in an investment phase: ROE of -53.31% and operating margin of -15.46% reflect commercial and R&D spending. The valuation (forward P/E 50.67) discounts Rezdiffra's success in a market with no approved direct competition.
The main risk is Rezdiffra's commercial execution: if adoption by physicians and patients does not meet expectations, the company, which is not yet profitable (operating margin -15.46%), may need dilutive financing and the current valuation (P/E 50.67) could adjust downward.
Context and risks
No recent news and no material exposure to current macro factors: the rise in long-term US rates does not significantly affect a biotech with modest debt (net debt/EBITDA 1.53) and cash to fund operations (liquidity 3.21). The business does not depend on commodities or shipping routes.
Is Madrigal Pharmaceuticals stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 157% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 21.5 | 4.1 | +423% |
| Price / sales | 8.8 | 3.4 | +157% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 1.1 out of 10 (median for Healthcare: 4.7).
Average analyst target: 682.11 USD, +39.9% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.3 (sector 5.5), Growth 10.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 50.7
- EV / EBITDA
- −33.6
- Price / book
- 21.5
- Price / sales
- 8.8
- Market cap
- 11.3B USD
- Enterprise value
- 10.8B USD
Profitability
- ROE
- −53.3%
- ROA
- −17.8%
- ROIC (approx.)
- −22.8%
- Gross margin
- 91.5%
- Operating margin
- −15.5%
- Net margin
- −25.3%
- Free cash flow
- −80.5M USD
- FCF yield
- −0.7%
Solvency
- Total debt
- 347.8M USD
- Net debt
- −491.0M USD
- Cash
- 838.8M USD
- EBITDA
- −321.1M USD
- Net debt / EBITDA
- 1.53
- Debt / equity
- 66.40
- Current ratio
- 3.21
- Quick ratio
- 2.75
Growth
- Revenue growth
- +71.2%
- EPS (TTM)
- −12.85 USD
- EPS (forward)
- 9.62 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- −1.05
- Analyst consensus
- Strong buy (18)
- Target price
- 682.11 USD
- 52-week range
- 393.61 – 615.00
Recent news
All MDGL news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Madrigal Pharmaceuticals
Is Madrigal Pharmaceuticals stock cheap or expensive?
On Price / sales, it trades 157% above the Healthcare median. Valuation score: 1.1 out of 10 (median for Healthcare: 4.7). Average analyst target: 682.11 USD, +39.9% versus the price. This is not investment advice.
What score does Madrigal Pharmaceuticals get on MeridIAn Screener?
It scores 4.9 out of 10, rank 1,756 of 2,130 (better than 17% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Valuation (1.1). Analysis of 08/10/2026.
How much is Madrigal Pharmaceuticals worth on the stock market?
Its market capitalisation is 11.3B USD and its enterprise value, debt included, is 10.8B USD.
How much debt does Madrigal Pharmaceuticals have?
It has more cash than debt: net cash of 491.0M USD.
Does Madrigal Pharmaceuticals pay a dividend?
It pays no dividend, or almost none.
How has Madrigal Pharmaceuticals stock performed over the last year?
It has risen 13.5% over the last year, excluding dividends. Over the last 52 weeks it has traded between 393.61 and 615.00 USD. Past performance does not guarantee future results.
What do analysts think of Madrigal Pharmaceuticals?
18 analysts cover it; their average recommendation is “Strong buy” and their average target is 682.11 USD (+39.9% versus the price). It is an estimate, not market data.